Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With Nab-Paclitaxel and Carboplatin in Advanced Non-Small Cell Lung Cancer

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.01256

Related search